WHO prematurely publishes remdesivir results

The World Health Organisation has accidentally leaked disappointing data from a trial of Gilead's coronavirus hopeful remdesivir in China.

According to media reports, the prematurely published information suggest that the drug failed to improve symptoms in patients with severe COVID-19 or reduce viral load, while side effects were also reported.

In a statement Gilead said the study had been removed from the WHO's site as study investigators "did not provide permission for the publication of the results".

"Furthermore, we believe the post included inappropriate characterisations of the study," the firm stressed.

"The study was terminated early due to low enrolment and, as a result, it was underpowered to enable statistically meaningful conclusions.

"As such, the study results are inconclusive, though trends in the data suggest a potential benefit for remdesivir, particularly among patients treated early in disease.

The news follows early data from a trial in the US which seemed to show some improvement in fever and respiratory symptoms in patients taking the drug.
 

CPhI China 2020 To Be Postponed to Dec. 16-18th,

Register as Visitor to the 20th Edition of CPhI China!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.